GH · available-data snapshot
Guardant Health, Inc. (GH): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for Guardant Health, Inc. (GH); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for GH?
We do not publish a fair value for Guardant Health, Inc.. What we can say from its filings and market data is below.
What is GH's TickerWorth Score?
Priced richly vs peers — the business scores well
Compared with Healthcare companies in US
Its strongest point: growing quickly. Its weakest: looks expensive on the numbers.
- Value · 19 of 100
Cheaper than 19% of Healthcare companies in US
- Price vs worth · 0 of 100
- Quality · 29 of 100
More profitable than 29% of Healthcare companies in US
- Financial health · 56 of 100
Financially stronger than 56% of Healthcare companies in US
- Growth · 87 of 100
Growing faster than 87% of Healthcare companies in US
- Momentum · 76 of 100
Outperformed 76% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $157.88
- Market cap
- $21,
186, 891, 776 - 52-week high
- $191.05
- 52-week low
- $65.96
- Currency
- USD
- Exchange
- NasdaqGS
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for Guardant Health, Inc. (GH) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, GH trades at a recent price of $157.88, a market capitalisation of about $21,186,891,776, sitting 73% of the way up its 52-week range ($65.96–$191.05), on the NasdaqGS.
The standard alternative to a DCF is relative valuation — comparing GH's trading multiples against a sector benchmark. Here that gives P/S of 17.9× (richer than the peer median of 6.2×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
Finally, a price-based read — explicitly not a valuation. GH is in a mixed trend, trading -17.4% from its 52-week high. Over the past year the stock is +125.9%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
GH vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | GH | Peer median | Read |
|---|---|---|---|
| P/S | 17.9× | 6.2× | richer than |
What does Guardant Health, Inc. do?
What does it do?
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It operates in the Diagnostics & Research industry (Healthcare sector), headquartered in United States. The company employs roughly 2,490 people.
How does it make money?
The business turns $1.2B in annual revenue into profit. Out of every $100 of sales, about $0 is left as operating profit (operating margin of -38.2%), after a 65% gross margin on the products/services it sells. After all costs, taxes and interest, -38.3% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: comfortably covers its short-term bills (4.0× current ratio), and is currently lossmaking.
Who at GH filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Azar Alex M II | Director | Open-market sale | $11,032.41 | Form 4 for Azar Alex M II (opens sec.gov in a new tab) | |
| Azar Alex M II | Director | Option exercise | — | Form 4 for Azar Alex M II (opens sec.gov in a new tab) | |
| Saia John G. | Chief Legal Officer | Option exercise | — | Form 4 for Saia John G. (opens sec.gov in a new tab) | |
| Saia John G. | Chief Legal Officer | Option exercise | — | Form 4 for Saia John G. (opens sec.gov in a new tab) | |
| Saia John G. | Chief Legal Officer | Option exercise | — | Form 4 for Saia John G. (opens sec.gov in a new tab) | |
| Saia John G. | Chief Legal Officer | Option exercise | — | Form 4 for Saia John G. (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.